IGC Pharma, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2023, the company’s fiscal first quarter, compared with the three months ended June 30, 2022. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
Business context
IGC is a clinical-stage pharmaceutical company with Life Sciences and Infrastructure segments. Its lead candidate, IGC-AD1, is in a Phase 2B trial for agitation associated with Alzheimer’s disease; TGR-63 remains in preclinical development. Life Sciences also sells OTC wellness products and provides white-label services. Infrastructure revenue comes from construction contracts and heavy-equipment rentals.
Key financial metrics
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Revenue | $555 | $212 |
| Gross profit / gross margin | $255 / 46% | $142 / 67% |
| SG&A | $1,647 | $1,550 |
| Research and development | $747 | $1,394 |
| Operating loss | ($2,139) | ($2,802) |
| Net loss | ($2,075) | ($2,785) |
| Basic and diluted loss per share | ($0.04) | ($0.05) |
| Cash used in operating activities | ($1,468) | ($2,196) |
Revenue increased 161% year over year. Life Sciences contributed $388 (70% of revenue), including $344 from white-label services and $44 from wellness and lifestyle products; Infrastructure contributed $167. Gross margin declined from 67% to 46%, which management attributed to revenue mix. R&D fell 46%, primarily because the prior-year quarter included a one-time non-cash expense; management said underlying R&D spending was approximately similar. Other income was $64, including approximately $43 from selling a fully depreciated property.
At June 30, cash and cash equivalents were $1,723, short-term investments $227, and working capital $2,947. Cash fell $1,473 from March 31. Total liabilities were $2,471, including $140 of long-term loans; the legacy EIDL loan bears 3.75% interest. The company reported total assets of $15,673 and stockholders’ equity of $13,202.
Liquidity, financing, and outlook
On June 30, IGC entered into a credit agreement allowing borrowings of up to $12 million, maturing June 30, 2024, with an option to renew. The facility was entirely unused at quarter-end; interest is based on the applicable certificate-of-deposit rate plus 1%. The company also entered into a private-placement agreement for 10 million shares at $0.30 per share, or approximately $3 million gross, subject to customary closing conditions including NYSE approval. The filing describes this transaction inconsistently as both an issuance/sale and a pending placement.
Management expects continued operating losses and negative operating cash flows in the near term, but estimates cash, the working-capital facility, and the equity investment will support operations beyond the 12 months following issuance of the financial statements. This estimate depends on assumptions that may prove incorrect. Management intends to seek additional financing, including private placements and ATM offerings; future equity financing may dilute shareholders. No specific financial guidance or trial completion timeline is provided.
Material developments, risks, and unusual items
- The Phase 2B IGC-AD1 trial is designed to assess safety and efficacy for Alzheimer’s-related agitation. Clinical outcomes, FDA approval, and the ability to fund trials are central uncertainties; management’s discussion of potential product efficacy is not a guarantee of results or regulatory approval.
- Approximately $397 of inventory was related to clinical trials. The company wrote off approximately $20 of inventory during the quarter for abnormal losses, recorded in SG&A.
- Approximately $10 million of restricted share units had been granted but not issued as of June 30; the filing reports $3.5 million of unrecognized compensation expense expected over a weighted-average five years. Potential equity securities were excluded from diluted EPS as anti-dilutive.
- After quarter-end, on July 20, a court granted IGC summary judgment in substantial part in the Apogee litigation, finding Apogee breached agreements and that IGC was entitled to damages and interest. Remaining issues include possible damages to Apogee and the amount of IGC’s recovery; the company denies liability for the remaining claim.
- After quarter-end, on July 11, Canada issued IGC a patent related to cannabinoid compositions and methods for treating pain and seizure disorders.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether the $3 million private placement closed, received NYSE approval, and resulted in the stated 10 million shares being issued; reconcile this with the filing’s reported 53,077,436 shares at June 30 and 53,916,604 shares outstanding as of July 24.
- Availability, conditions, interest cost, and renewal prospects for the $12 million credit facility; it was unused at quarter-end and is not cash on hand.
- Cash burn and the assumptions underlying management’s estimate that available resources support operations beyond 12 months.
- Progress, enrollment, costs, and results of the IGC-AD1 Phase 2B trial, as well as the evidence and development plans for TGR-63.
- Collection prospects for $951 of vendor claims receivable, which the company says may be challenging to collect within 12 months.
- Resolution and potential financial impact of the remaining Apogee litigation issues, plus the degree of dilution from the placement, restricted share units, and any future fundraising.